CareLit · DOI-Nachweis · Zeitschrift für Gastroenterologie
Treatment of Genotype 1 Hepatitis C patients with severe fibrosis or compensated cirrhosis: the telaprevir early access program in patients from Austria and Switzerland
DOI 10.1055/s-0033-1347404
Bibliografische Angaben
Nachweis in CareLit
Autor:innenA Maieron, W Vogel, A Cerny, R Stauber, B Müllhaupt, F Negro, A Hill, J Läuffer, D Semela
ZeitschriftZeitschrift für Gastroenterologie
Ausgabe05/2013
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Background: HEP3002 is an ongoing, open-label, early access program of telaprevir in 16 countries, for adult patients with genotype 1 chronic hepatitis C with severe fibrosis or compensated cirrhosis. Methods: Patients were treated with telaprevir, pegylated interferon-alpha and ribavirin (PR) for 12 weeks, followed by PR alone. Liver biopsy or non-invasive tests showing severe fibrosis or cirrhosis and platelet cou…
Zitieren
Zitierempfehlung
A Maieron, W Vogel, A Cerny, R Stauber, B Müllhaupt, F Negro, A Hill, J Läuffer, D Semela (2013) Treatment of Genotype 1 Hepatitis C patients with severe fibrosis or compensated cirrhosis: the telaprevir early access program in patients from Austria and Switzerland. Zeitschrift für Gastroenterologie (05). https://doi.org/10.1055/s-0033-1347404
Mit CareLit weiterarbeiten